Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sepantroniumbromid til behandling af højgradigt B-celle lymfom

2. november 2026 opdateret af: Cothera Bioscience, Inc

En fase 2, multicenter, åben-label dosisvarierende undersøgelse af sepantroniumbromid hos patienter med recidiverende/refraktær c-Myc-omlejret højgradigt B-celle lymfom (HGBCL)

This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multi-center, open label, dose-ranging Phase 2 study evaluating the safety and efficacy of SepB in patients with relapsed/refractory c-Myc rearranged HGBCL.

Cohorts of three patients will be enrolled at each dose level for SepB with expansion to six patients, if necessary, to assess toxicity.

Following the completion of 2 cycles of treatment of each cohort, an independent Data Monitoring Committee (DMC) will review the safety data to assess study drug related toxicities from the current cohort. Following this review, a decision will be made to continue dose escalation to the next dose level, to declare that a given dose level is the level of dose-limiting toxicity (DLT) or to further explore toxicity at the dose level in question by enrolling additional subjects to a maximum of six subjects at that level.

An additional 6 patients will be enrolled at the recommended Phase 2 dose (RP2D). The RP2D will be established on the basis of the maximally tolerated dose between the two specified dose levels as well as other relevant data, including clinical signals of activity, pharmacokinetic (PK) and pharmacodynamic (PD) data.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

14

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Beijing, Kina
        • Beijing Cancer Hospital
      • Guangzhou, Kina
        • Sun Yat-sen University Cancer Center
      • Henan, Kina
        • Henan Cancer Hospital
      • Pudong, Kina
        • Shanghai East Hospital
      • Tianjin, Kina
        • Tianjin Cancer Hospital
      • Wuhan, Kina
        • Tongji Hospital
      • Busan, Sydkorea
        • Dong-A University Hospital
      • Busan, Sydkorea
        • Inje University Haeundae Paik hospital
      • Seoul, Sydkorea
        • Samsung Medical Center
      • Seoul, Sydkorea
        • Seoul National University Hospital
      • Seoul, Sydkorea
        • Seoul St.Mary's Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Confirmed histologic diagnosis of c-Myc rearranged high-grade B-cell lymphoma
  • Relapse or refractory disease after at least one previous line of therapy
  • Measurable disease as defined by 2014 Lugano classification
  • ECOG performance status of 0-2
  • Acceptable coagulation parameters

Exclusion Criteria:

  • Allogeneic transplant within 3 months
  • Autologous transplant without resolution of post-transplant cytopenias
  • Known CNS involvement
  • Average QT/QTc interval duration > 450 msec
  • Inadequate marrow, hepatic or renal function
  • Unresolved Grade 2 or greater toxicities from prior anticancer therapy
  • Radiotherapy within prior 4 weeks
  • Requires systemic immunosuppressive therapy
  • Positive for Hepatis B or Hepatis C
  • Seropositive for HIV

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cohort 1

Cohort 1 will receive a dose of 3.6 mg/m2/day of sepantronium bromide

continuous intravenous infusion

Andre navne:
  • PC-002
Eksperimentel: Cohort 2

Cohort 1 will receive a dose of 4.8 mg/m2/day of sepantronium bromide

continuous intravenous infusion

Andre navne:
  • PC-002
Eksperimentel: Recommended Phase 2 Dose - Cohort 3

The recommended Phase 2 dose will be established based on the safety, pharmacokinetic and pharmacodynamic data from Cohort 1 and Cohort 2

continuous intravenous infusion

Andre navne:
  • PC-002

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety and tolerability and recommended Phase 2 dose of sepantronium bromide
Tidsramme: From time of signing informed consent through 30 days after the last dose of study drug, an average of 6 months

Frequency, severity and relatedness of adverse events and the frequency of adverse events requiring discontinuation of study drug or dose reductions

From time of signing informed consent through 30 days after the last dose of study drug, an average of 6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall response rate
Tidsramme: From first dose through the last dose of study drug, an average of 6 months

The ORR is defined as the percentage of participants who achieve either a Partial Response or Complete Response at any time during the treatment phase

From first dose through the last dose of study drug, an average of 6 months
Complete response rate
Tidsramme: From first dose of study drug through the last dose of study drug, an average of 6 months

Percentage of patients who experience a confirmed Complete Response at any time during the treatment phase

From first dose of study drug through the last dose of study drug, an average of 6 months
Duration of response
Tidsramme: From first dose of study drug through to time of progression, an average of 6 months

Time from the first documentation of a Complete Response or a Partial Response until the time to objective tumor progression

From first dose of study drug through to time of progression, an average of 6 months
Clinical benefit rate
Tidsramme: From first dose of study drug through the last dose of study drug, an average of 6 months

Proportion of patients who achieve a Complete Response, Partial Response or Stable Disease during the treatment phase

From first dose of study drug through the last dose of study drug, an average of 6 months
Overall survival
Tidsramme: From first dose of study drug through date of death, irrespective of cause, an average of 6 months

The time from the first dose of study drug until death from any cause or date of last follow-up for living and lost to follow-up patients

From first dose of study drug through date of death, irrespective of cause, an average of 6 months
Progression Free Survival
Tidsramme: From first dose of study drug through relapse, disease progression or death due to any cause, an average of 12 months

The time from first dose until relapse, disease progression or death due to any cause

From first dose of study drug through relapse, disease progression or death due to any cause, an average of 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Vernon Jiang, PhD, Cothera Bioscience

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. december 2022

Primær færdiggørelse (Faktiske)

12. februar 2025

Studieafslutning (Faktiske)

12. februar 2025

Datoer for studieregistrering

Først indsendt

16. februar 2022

Først indsendt, der opfyldte QC-kriterier

27. februar 2022

Først opslået (Faktiske)

2. marts 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • PC002-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)

IPD-delingstidsramme

Beginning 9 months and ending 36 months following article publication.

IPD-delingsadgangskriterier

Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .